Ocular Drug Delivery Technology Market: By Technology, Topical, Intra Ocular Implants, Iontophoresis, Punctual Plugs and Situ Gel), By Disease Indication, and Region Forecast 2019-2030
Ocular Drug Delivery Technology Market size was valued at US$ 17.404 million in 2023 and is expected to reach US$ 25.042 million by 2030, at a CAGR of 8.4% from 2024-2030. The treatment of ophthalmic illnesses is linked to ocular medicine delivery. Ophthalmic illnesses impact several areas of the eye anatomy, which are primarily divided into anterior and posterior segments based on their location. Ocular medications are applied directly to the affected area or near the affected area to allow for quick absorption and action. For treating anterior eye segment illnesses, topical ocular medication formulations are largely accessible in liquid form, such as solutions, suspensions, and emulsions.
More modern procedures, like as implants and injections, are used to treat posterior segment problems. Ophthalmic drug delivery technologies has become most interesting challenging for the scientists due to the unique anatomy, physiology and biochemistry of the eye. The global market is primarily driven by increase in eye related diseases such as macular degeneration, and glaucoma coupled with the preference of patients and physicians in the usage of targeted ocular drug delivery technologies. this report studies global Market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.
Study Period
2024-2030Base Year
2023CAGR
8.4%Largest Market
North-AmericaFastest Growing Market
Europe
The low bioavailability of drugs in traditional ocular therapies, an increase in the incidence of glaucoma and macular degeneration, growing demand for targeted ocular drug delivery techniques, and an increase in the number of approvals from government regulations for new ocular drug delivery techniques are the major factors driving the growth of the global ocular drug delivery technology market. Favorable reimbursement rules and increased funding for the development of innovative drug delivery systems may aid market expansion. The solidity of the implants, on the other hand, can cause discomfort, as well as drug dilution, irritation, and severe lachrymation, which could limit market expansion.
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 17.404 million |
|
Market Size in 2030 |
US$ 25.042 million |
|
Market CAGR |
8.4% |
|
By Technology |
|
|
By Disease Indication |
|
|
By End User |
|
Download Free Sample Report
The ocular drug delivery technology market size valued US$ 17.404 million in 2023 and is projected to reach US$ 25.042 million by 2030, at a CAGR of 8.4%.
The ocular drug delivery technology market's key players are: Taiwan Liposome Company, Ltd. (Taiwan) Valeant Pharmaceuticals International, Inc. (U.S.) Graybug Vision Inc. (U.S.) Ocular Therapeutix, Inc. (U.S.) Clearside Biomedical, Inc. (U.S.) EyeGate Pharma (U.S.) Alimera Sciences (U.S.) Allergan, Plc (Ireland) Envisia Therapeutics (U.S.)
The ocular drug delivery technology market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Ocular Drug Delivery Technology Market Introduction |
| 2.1. Global Ocular Drug Delivery Technology Market - Taxonomy |
| 2.2. Global Ocular Drug Delivery Technology Market - Definitions |
| 2.2.1. Technology |
| 2.2.2. Disease Indication |
| 2.2.3. End User |
| 2.2.4. Region |
| 3. Global Ocular Drug Delivery Technology Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Key Developments |
| 4. Global Ocular Drug Delivery Technology Market By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 4.1. Ocular Inserts |
| 4.1.1. Erodible |
| 4.1.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.1.3. Market Opportunity Analysis |
| 4.1.2. Non-Erodible |
| 4.1.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.2.3. Market Opportunity Analysis |
| 4.2. Topical |
| 4.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.3. Market Opportunity Analysis |
| 4.3. Intra Ocular Implants |
| 4.3.1. Non-Biodegradable |
| 4.3.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.3.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.3.1.3. Market Opportunity Analysis |
| 4.3.2. Bio Degradable |
| 4.3.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.3.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3.2.3. Market Opportunity Analysis |
| 4.4. Ionotophoresis |
| 4.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.4.3. Market Opportunity Analysis |
| 4.5. Punctal Plugs (Tear Duct Plugs) |
| 4.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.5.3. Market Opportunity Analysis |
| 4.6. In Situ Gel |
| 4.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.6.3. Market Opportunity Analysis |
| 5. Global Ocular Drug Delivery Technology Market By Disease Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Diabetic Retinopathy |
| 5 1 1 Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Glaucoma |
| 5.2.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 5.3. Macular Degeneration |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Cataract |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Ocular Drug Delivery Technology Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Ambulatory Surgical Centers |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Hospitals |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Ophthalmic Centers |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Ocular Drug Delivery Technology Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. MEA |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Ocular Drug Delivery Technology Market - Opportunity Analysis Index, By Disease Indication, Technology, End User, , , , , and Region, 2024 - 2030 |
| 8. North America Ocular Drug Delivery Technology Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Technology Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Ocular Inserts |
| 8.1.1.1. Erodible |
| 8.1.1.2. Non-Erodible |
| 8.1.2. Topical |
| 8.1.3. Intra Ocular Implants |
| 8.1.3.1. Non-Biodegradable |
| 8.1.3.2. Bio Degradable |
| 8.1.4. Ionotophoresis |
| 8.1.5. Punctal Plugs (Tear Duct Plugs) |
| 8.1.6. In Situ Gel |
| 8.2. Disease Indication Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Diabetic Retinopathy |
| 8.2.2. Glaucoma |
| 8.2.3. Macular Degeneration |
| 8.2.4. Cataract |
| 8.3. End User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1. Ambulatory Surgical Centers |
| 8.3.2. Hospitals |
| 8.3.3. Ophthalmic Centers |
| 8.4. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.4.1. USA |
| 8.4.2. Canada |
| 9. Europe Ocular Drug Delivery Technology Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Technology Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Ocular Inserts |
| 9.1.1.1. Erodible |
| 9.1.1.2. Non-Erodible |
| 9.1.2. Topical |
| 9.1.3. Intra Ocular Implants |
| 9.1.3.1. Non-Biodegradable |
| 9.1.3.2. Bio Degradable |
| 9.1.4. Ionotophoresis |
| 9.1.5. Punctal Plugs (Tear Duct Plugs) |
| 9.1.6. In Situ Gel |
| 9.2. Disease Indication Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Diabetic Retinopathy |
| 9.2.2. Glaucoma |
| 9.2.3. Macular Degeneration |
| 9.2.4. Cataract |
| 9.3. End User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Ambulatory Surgical Centers |
| 9.3.2. Hospitals |
| 9.3.3. Ophthalmic Centers |
| 9.4. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1. Germany |
| 9.4.2. France |
| 9.4.3. Italy |
| 9.4.4. Spain |
| 9.4.5. UK |
| 9.4.6. Rest of Europe |
| 10. Asia Pacific Ocular Drug Delivery Technology Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Technology Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Ocular Inserts |
| 10.1.1.1. Erodible |
| 10.1.1.2. Non-Erodible |
| 10.1.2. Topical |
| 10.1.3. Intra Ocular Implants |
| 10.1.3.1. Non-Biodegradable |
| 10.1.3.2. Bio Degradable |
| 10.1.4. Ionotophoresis |
| 10.1.5. Punctal Plugs (Tear Duct Plugs) |
| 10.1.6. In Situ Gel |
| 10.2. Disease Indication Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Diabetic Retinopathy |
| 10.2.2. Glaucoma |
| 10.2.3. Macular Degeneration |
| 10.2.4. Cataract |
| 10.3. End User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Ambulatory Surgical Centers |
| 10.3.2. Hospitals |
| 10.3.3. Ophthalmic Centers |
| 10.4. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1. China |
| 10.4.2. Japan |
| 10.4.3. South Korea |
| 10.4.4. India |
| 10.4.5. Rest of APAC |
| 11. Latin America Ocular Drug Delivery Technology Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Technology Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Ocular Inserts |
| 11.1.1.1. Erodible |
| 11.1.1.2. Non-Erodible |
| 11.1.2. Topical |
| 11.1.3. Intra Ocular Implants |
| 11.1.3.1. Non-Biodegradable |
| 11.1.3.2. Bio Degradable |
| 11.1.4. Ionotophoresis |
| 11.1.5. Punctal Plugs (Tear Duct Plugs) |
| 11.1.6. In Situ Gel |
| 11.2. Disease Indication Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Diabetic Retinopathy |
| 11.2.2. Glaucoma |
| 11.2.3. Macular Degeneration |
| 11.2.4. Cataract |
| 11.3. End User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Ambulatory Surgical Centers |
| 11.3.2. Hospitals |
| 11.3.3. Ophthalmic Centers |
| 11.4. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1. Brazil |
| 11.4.2. Mexico |
| 11.4.3. Argentina |
| 11.4.4. Rest of Latin America |
| 12. MEA Ocular Drug Delivery Technology Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Technology Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Ocular Inserts |
| 12.1.1.1. Erodible |
| 12.1.1.2. Non-Erodible |
| 12.1.2. Topical |
| 12.1.3. Intra Ocular Implants |
| 12.1.3.1. Non-Biodegradable |
| 12.1.3.2. Bio Degradable |
| 12.1.4. Ionotophoresis |
| 12.1.5. Punctal Plugs (Tear Duct Plugs) |
| 12.1.6. In Situ Gel |
| 12.2. Disease Indication Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Diabetic Retinopathy |
| 12.2.2. Glaucoma |
| 12.2.3. Macular Degeneration |
| 12.2.4. Cataract |
| 12.3. End User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Ambulatory Surgical Centers |
| 12.3.2. Hospitals |
| 12.3.3. Ophthalmic Centers |
| 12.4. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1. GCC Countries |
| 12.4.2. South Africa |
| 12.4.3. Rest of MEA |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Taiwan Liposome Company, Ltd. (Taiwan) |
| 13.2.2. Valeant Pharmaceuticals International, Inc. (U.S.) |
| 13.2.3. Graybug Vision Inc. (U.S.) |
| 13.2.4. Ocular Therapeutix, Inc. (U.S.) |
| 13.2.5. Clearside Biomedical, Inc. (U.S.) |
| 13.2.6. EyeGate Pharma (U.S.) |
| 13.2.7. Alimera Sciences (U.S.) |
| 13.2.8. Allergan, Plc (Ireland) |
| 13.2.9. Envisia Therapeutics (U.S.) |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
